New hope for high-risk MDS: phase 3 trial of lisaftoclax combo launches globally
NCT ID NCT06641414
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This study tests whether adding the experimental drug lisaftoclax to standard chemotherapy (azacitidine) helps people with newly diagnosed, higher-risk myelodysplastic syndrome (a serious blood cancer) live longer. About 490 adults worldwide will be randomly assigned to receive either the combination or a placebo plus chemotherapy. The main goal is to see if the new combination improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.